The UK and US have hammered out a major bilateral deal that will preserve zero tariffs on UK medicine exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key exports will remain at zero for a duration of three years.
This development comes after earlier statements to significantly raise tariffs on branded pharmaceutical imports, with increases floated reaching one hundred percent.
"This agreement with the United Kingdom bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a statement said.
Trade Impact
Drugs constitute one of the the United Kingdom's largest export categories to the United States, which is easily the primary buyer for major British pharmaceutical firms.
Export figures indicate that in the year to the end of September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This amount represented 17.4% of total UK exports in that timeframe.
"This guarantee safeguards jobs, increases capital expenditure and facilitates the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Detailed UK Commitments
The pact entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded 20%.
Recent Tensions
The pact comes amid a long-running row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
The disagreement were heightened by assertions that American customers were charged significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or cancelled, while substantial investments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on treatments, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
